Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2026-01-05 @ 6:01 PM
Study NCT ID:
NCT00650832
Status:
COMPLETED
Last Update Posted:
2011-06-15
First Post:
2008-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-10
Start Date Type:
None
Primary Completion Date:
2005-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-07
Completion Date Type:
ACTUAL
First Submit Date:
2008-03-28
First Submit QC Date:
None
Study First Post Date:
2008-04-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2011-06-15
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2011-06-02
Last Update Post Date:
2011-06-15
Last Update Post Date Type:
ESTIMATED